版本:
中国

BRIEF-Aimmune Therapeutics reports on up-dosing in its ongoing phase 3 palisade trial of ar101 for peanut allergy

June 12 Aimmune Therapeutics Inc:

* Aimmune Therapeutics reports on up-dosing in its ongoing phase 3 palisade trial of ar101 for peanut allergy

* Aimmune Therapeutics Inc - final study visits projected around year-end 2017; topline data expected in q1 of 2018

* Aimmune Therapeutics Inc - more than 97 percent of patients currently on study are through up-dosing phase Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐